Você procurou por: pulmonaalihypertensiota (Finlandês - Inglês)

teho pulmonaalihypertensiota sairastavilla aikuispotilailla
efficacy in adult patients with pulmonary hypertension

laskimoon annetun sildenafiilin teho pulmonaalihypertensiota sairastavilla aikuispotilailla
efficacy of intravenous sildenafil in adult patients with pulmonary arterial hypertension (pah)

tutkimukseen otetuista potilasta 108 sairasti primaarista pulmonaalihypertensiota ja 95 sekundaarista pulmonaalihypertensiota.
108 of the patients included were diagnosed with primary pulmonary hypertension, 95 were diagnosed with secondary pulmonary hypertension of which 56 were associated with chronic thromboembolic disease, 34 with connective tissue disease (including crest and scleroderma) and 4 were considered appetite suppressant drug related.

pulmonaalihypertensiopotilaihin kuuluivat sekä primaarista pulmonaalihypertensiota sairastavat että sidekudossairauteen liittyvää pulmonaalihypertensiota sairastavat potilaat.
the pah patients included those with primary pah, and pah associated with connective tissue disease.

pulmonaalihypertensiota sairastavilla potilailla huippupitoisuudet plasmassa saavutetaan yleensä 1-4 tunnin kuluessa.
in pah patients, peak plasma concentrations are generally achieved within 1-4 hours.

volibris on tarkoitettu pulmonaalihypertensiota (pah) sairastavien potilaiden hoitoon parantamaan fyysistä suorituskykyä.
volibris is used for the treatment of patients with pulmonary arterial hypertension (pah) to improve exercise capacity (the ability to carry out physical activity).

hoidon saa aloittaa vain pulmonaalihypertension hoitoon perehtynyt lääkäri.
treatment must be initiated by a physician experienced in the treatment of pah.